New Immunotherapy Combination for Advanced Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma (a type of cancer) in your head or neck that has returned or spread to other parts of your body
- You have already received at least one previous treatment (chemotherapy or other systemic therapy) for your recurrent or metastatic cancer
- You are between 18 and 75 years old
- You are in reasonably good health overall (ECOG performance status 0–2, meaning you can carry out most normal daily activities)
- Your doctor can see at least one measurable tumor on imaging scans
- Your blood counts, liver function, and kidney function are adequate; your thyroid hormones are normal or controlled by medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer. The goal is to see if adding these drugs improves the chances of controlling the cancer.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.